Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ALPA

ALPA LAB

HealthcarePharmaceuticals & Biotechnology₹109 cr market cap
₹50.64 ▼ -1.84% today As of 19 Nov 2026
52-week low ₹46.4652-week high ₹86.69

-40.5% from the 52-week high · +11.0% above the low

Alpa Laboratories Ltd. is a pharmaceutical holding company, which engages in the manufactures of drugs and chemicals. The company is headquartered in Indore, Madhya Pradesh. The company went IPO on 2007-08-01. The firm is engaged in manufacturing pharmaceutical finished dosage forms. Its product range includes a variety of generic and over the counter (OTC) drugs in various finished dosage forms for both human and veterinary use. For human use it offers capsules such as Ampicillin Capsule IP/BP, Amoxycillin Trihydrate Capsule IP/BP, Cloxacillin Capsules IP/BP and Piroxicam Capsules IP BP; creams, gels and ointments, which include Lidocaine Hydrochloride Jelly IP/USP, Nitrofurazone Cream USP, Miconazole Cream IP/BP and Clobetasole Ointment/Cream BP; ear and eye drops, such as Benzylpenicillin Inj. IP/BP and Benzathine Penicillin Inj. IP/BP, and tablets, such as Albendazole Tablet IP/USP, Paracetamol Tablet IP/BP and Tinidazole Tablets IP/BP. Its veterinary products include boluses, such as Alpamin Bolus and Alpazole Bolus, and injections, such as Atropine Inj. B.Vet.C and others.

The short version. ALPA LAB reported revenue of ₹31 crore for Sep 2026, up 19.2% from a year earlier. Return on equity was 8.1% in Mar 2026. Promoter holding was 57.19% in Sep 2026, down 0.10 points over 8 quarters.

1 · The price

How has the stock traded?

ALPA LAB trades 40.5% below its 52-week high and 11.0% above its 52-week low.

Change over period: —

1M-1.3%
3M-15.5%
6M-24.4%
1Y-36.4%

2 · The business

Is it growing?

Sales, year on year+19.2%

Sep 2026 revenue of ₹31 cr.

Net margin-6.0%

6.4 pts lower than a year earlier.

3-year growth5.9% profit

Revenue compounded at 5.9% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3124312926194026
Net profit-2112012-29
Net margin %-6.04.14.46.60.461.6-5.334.0
EPS (₹)-0.880.470.660.90.055.59-1.014.23

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue106112109921129886
Net profit152017131472
Net margin %14.217.315.413.712.67.42.2
EPS (₹)7.139.277.976.06.73.440.88

3 · The quality

How well does it turn capital into profit?

Return on equity was 8.1% in Mar 2026; debt to equity is 0.01.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %8.111.411.09.4
Return on capital %8.914.713.611.8
EBITDA margin %15.720.718.617.1
Net margin %12.314.413.612.3

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR5.9%3.6%
Profit CAGR5.9%15.7%
Debt to equity0.01
Interest cover65.7x
Current ratio4.01
P/E ratio25.3

4 · The owners

Who holds it, and are they adding?

Promoter holding57.19%

Down 0.1 pts over 8 quarters.

Foreign institutions0.35%

Unchanged over 8 quarters.

Domestic institutions0.07%

Up 0.07 pts over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter57.2957.2957.2957.2957.2957.1957.1957.19-0.1
FII0.350.40.360.350.360.380.350.350.0
DII0000000.070.07+0.07
Public42.3542.3142.3442.3542.3542.4342.3942.39+0.04

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ALPA LAB are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ALPA LAB

What is the ALPA LAB share price?

ALPA LAB (ALPA) last closed at ₹50.64, down 1.84% on the day. Its 52-week range is ₹46.46 to ₹86.69.

What is the market cap of ALPA LAB?

ALPA LAB has a market capitalisation of about ₹109 crore. Its price-to-earnings ratio is 25.3.

How are ALPA LAB's latest results?

ALPA LAB reported revenue of ₹31 crore for Sep 2026, up 19.2% from a year earlier. Return on equity was 8.1% in Mar 2026. Promoter holding was 57.19% in Sep 2026, down 0.10 points over 8 quarters.

Who owns ALPA LAB?

As of Sep 2026, shareholding was: Promoter 57.19%, FII 0.35%, DII 0.07%, Public 42.39%.

How many mutual funds hold ALPA LAB?

0 mutual fund schemes held ALPA LAB in October 2026. That compares with 0 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.